Gemcitabine pharmacogenomics: Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics

Neslihan Aygun Kocabas, Pinar Aksoy, Linda L. Pelleymounter, Irene Moon, Jeong Seon Ryu, Judith A. Gilbert, Oreste Ezequel Salavaggione, Bruce W. Eckloff, Eric D Wieben, Vivien Yee, Richard M Weinshilboum, Matthew M. Ames

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Gemcitabine and other cytidine antimetabolites require metabolic activation by phosphorylation. Deoxycytidine kinase (DCK) and cytidine monophosphate kinase (CMPK) catalyze these reactions. We have applied a genotype-to-phenotype strategy to study DCK and CMPK pharmacogenomics. Specifically, we resequenced DCK and CMPK using 240 DNA samples, 60 each from African-American, Caucasian-American, Han Chinese-American, and Mexican-American subjects. We observed 28 DCK polymorphisms and 28 polymorphisms in CMPK, 33 of which were novel. Expression in COS-1 cells showed that variant allozyme enzyme activities ranged from 32 to 105% of the wild type (WT) for DCK and from 78 to 112% of WT for CMPK - with no significant differences in apparent Km values for either enzyme except for a DCK Val24/Ser122 double variant allozyme. Relative levels of DCK and CMPK immunoreactive protein in the COS-1 cells paralleled relative levels of enzyme activity and were significantly correlated for DCK (Rp = 0.89, P = 0.0004) but not for CMPK (Rp = 0.82, P = 0.095). The results of an analysis of DCK and CMPK structural models were compatible with the observed functional consequences of sequence alterations in variant allozymes. We also confirmed that the CMPK protein expressed in COS-1 cells and in a rabbit reticulocyte lysate was 196 rather than 228 amino acids in length. In summary, we determined common sequence variations in DCK and CMPK and systematically evaluated their functional implications. These gene sequence differences may contribute to variations in the metabolic activation of gemcitabine and other cytidine antimetabolites.

Original languageEnglish (US)
Pages (from-to)1951-1959
Number of pages9
JournalDrug Metabolism and Disposition
Volume36
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

gemcitabine
Deoxycytidine Kinase
Pharmacogenetics
Deoxycytidine Monophosphate
Genomics
Genes
COS Cells
Isoenzymes
Antimetabolites
Cytidine
Enzyme activity
Polymorphism
Enzymes
Chemical activation
cytidylate kinase
Phosphorylation
Asian Americans
Reticulocytes
Structural Models

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Kocabas, N. A., Aksoy, P., Pelleymounter, L. L., Moon, I., Ryu, J. S., Gilbert, J. A., ... Ames, M. M. (2008). Gemcitabine pharmacogenomics: Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metabolism and Disposition, 36(9), 1951-1959. https://doi.org/10.1124/dmd.108.020925

Gemcitabine pharmacogenomics : Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. / Kocabas, Neslihan Aygun; Aksoy, Pinar; Pelleymounter, Linda L.; Moon, Irene; Ryu, Jeong Seon; Gilbert, Judith A.; Salavaggione, Oreste Ezequel; Eckloff, Bruce W.; Wieben, Eric D; Yee, Vivien; Weinshilboum, Richard M; Ames, Matthew M.

In: Drug Metabolism and Disposition, Vol. 36, No. 9, 09.2008, p. 1951-1959.

Research output: Contribution to journalArticle

Kocabas, NA, Aksoy, P, Pelleymounter, LL, Moon, I, Ryu, JS, Gilbert, JA, Salavaggione, OE, Eckloff, BW, Wieben, ED, Yee, V, Weinshilboum, RM & Ames, MM 2008, 'Gemcitabine pharmacogenomics: Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics', Drug Metabolism and Disposition, vol. 36, no. 9, pp. 1951-1959. https://doi.org/10.1124/dmd.108.020925
Kocabas, Neslihan Aygun ; Aksoy, Pinar ; Pelleymounter, Linda L. ; Moon, Irene ; Ryu, Jeong Seon ; Gilbert, Judith A. ; Salavaggione, Oreste Ezequel ; Eckloff, Bruce W. ; Wieben, Eric D ; Yee, Vivien ; Weinshilboum, Richard M ; Ames, Matthew M. / Gemcitabine pharmacogenomics : Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. In: Drug Metabolism and Disposition. 2008 ; Vol. 36, No. 9. pp. 1951-1959.
@article{dedb73e3dc6643359df93732138feb2a,
title = "Gemcitabine pharmacogenomics: Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics",
abstract = "Gemcitabine and other cytidine antimetabolites require metabolic activation by phosphorylation. Deoxycytidine kinase (DCK) and cytidine monophosphate kinase (CMPK) catalyze these reactions. We have applied a genotype-to-phenotype strategy to study DCK and CMPK pharmacogenomics. Specifically, we resequenced DCK and CMPK using 240 DNA samples, 60 each from African-American, Caucasian-American, Han Chinese-American, and Mexican-American subjects. We observed 28 DCK polymorphisms and 28 polymorphisms in CMPK, 33 of which were novel. Expression in COS-1 cells showed that variant allozyme enzyme activities ranged from 32 to 105{\%} of the wild type (WT) for DCK and from 78 to 112{\%} of WT for CMPK - with no significant differences in apparent Km values for either enzyme except for a DCK Val24/Ser122 double variant allozyme. Relative levels of DCK and CMPK immunoreactive protein in the COS-1 cells paralleled relative levels of enzyme activity and were significantly correlated for DCK (Rp = 0.89, P = 0.0004) but not for CMPK (Rp = 0.82, P = 0.095). The results of an analysis of DCK and CMPK structural models were compatible with the observed functional consequences of sequence alterations in variant allozymes. We also confirmed that the CMPK protein expressed in COS-1 cells and in a rabbit reticulocyte lysate was 196 rather than 228 amino acids in length. In summary, we determined common sequence variations in DCK and CMPK and systematically evaluated their functional implications. These gene sequence differences may contribute to variations in the metabolic activation of gemcitabine and other cytidine antimetabolites.",
author = "Kocabas, {Neslihan Aygun} and Pinar Aksoy and Pelleymounter, {Linda L.} and Irene Moon and Ryu, {Jeong Seon} and Gilbert, {Judith A.} and Salavaggione, {Oreste Ezequel} and Eckloff, {Bruce W.} and Wieben, {Eric D} and Vivien Yee and Weinshilboum, {Richard M} and Ames, {Matthew M.}",
year = "2008",
month = "9",
doi = "10.1124/dmd.108.020925",
language = "English (US)",
volume = "36",
pages = "1951--1959",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "9",

}

TY - JOUR

T1 - Gemcitabine pharmacogenomics

T2 - Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics

AU - Kocabas, Neslihan Aygun

AU - Aksoy, Pinar

AU - Pelleymounter, Linda L.

AU - Moon, Irene

AU - Ryu, Jeong Seon

AU - Gilbert, Judith A.

AU - Salavaggione, Oreste Ezequel

AU - Eckloff, Bruce W.

AU - Wieben, Eric D

AU - Yee, Vivien

AU - Weinshilboum, Richard M

AU - Ames, Matthew M.

PY - 2008/9

Y1 - 2008/9

N2 - Gemcitabine and other cytidine antimetabolites require metabolic activation by phosphorylation. Deoxycytidine kinase (DCK) and cytidine monophosphate kinase (CMPK) catalyze these reactions. We have applied a genotype-to-phenotype strategy to study DCK and CMPK pharmacogenomics. Specifically, we resequenced DCK and CMPK using 240 DNA samples, 60 each from African-American, Caucasian-American, Han Chinese-American, and Mexican-American subjects. We observed 28 DCK polymorphisms and 28 polymorphisms in CMPK, 33 of which were novel. Expression in COS-1 cells showed that variant allozyme enzyme activities ranged from 32 to 105% of the wild type (WT) for DCK and from 78 to 112% of WT for CMPK - with no significant differences in apparent Km values for either enzyme except for a DCK Val24/Ser122 double variant allozyme. Relative levels of DCK and CMPK immunoreactive protein in the COS-1 cells paralleled relative levels of enzyme activity and were significantly correlated for DCK (Rp = 0.89, P = 0.0004) but not for CMPK (Rp = 0.82, P = 0.095). The results of an analysis of DCK and CMPK structural models were compatible with the observed functional consequences of sequence alterations in variant allozymes. We also confirmed that the CMPK protein expressed in COS-1 cells and in a rabbit reticulocyte lysate was 196 rather than 228 amino acids in length. In summary, we determined common sequence variations in DCK and CMPK and systematically evaluated their functional implications. These gene sequence differences may contribute to variations in the metabolic activation of gemcitabine and other cytidine antimetabolites.

AB - Gemcitabine and other cytidine antimetabolites require metabolic activation by phosphorylation. Deoxycytidine kinase (DCK) and cytidine monophosphate kinase (CMPK) catalyze these reactions. We have applied a genotype-to-phenotype strategy to study DCK and CMPK pharmacogenomics. Specifically, we resequenced DCK and CMPK using 240 DNA samples, 60 each from African-American, Caucasian-American, Han Chinese-American, and Mexican-American subjects. We observed 28 DCK polymorphisms and 28 polymorphisms in CMPK, 33 of which were novel. Expression in COS-1 cells showed that variant allozyme enzyme activities ranged from 32 to 105% of the wild type (WT) for DCK and from 78 to 112% of WT for CMPK - with no significant differences in apparent Km values for either enzyme except for a DCK Val24/Ser122 double variant allozyme. Relative levels of DCK and CMPK immunoreactive protein in the COS-1 cells paralleled relative levels of enzyme activity and were significantly correlated for DCK (Rp = 0.89, P = 0.0004) but not for CMPK (Rp = 0.82, P = 0.095). The results of an analysis of DCK and CMPK structural models were compatible with the observed functional consequences of sequence alterations in variant allozymes. We also confirmed that the CMPK protein expressed in COS-1 cells and in a rabbit reticulocyte lysate was 196 rather than 228 amino acids in length. In summary, we determined common sequence variations in DCK and CMPK and systematically evaluated their functional implications. These gene sequence differences may contribute to variations in the metabolic activation of gemcitabine and other cytidine antimetabolites.

UR - http://www.scopus.com/inward/record.url?scp=50049105739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049105739&partnerID=8YFLogxK

U2 - 10.1124/dmd.108.020925

DO - 10.1124/dmd.108.020925

M3 - Article

C2 - 18556440

AN - SCOPUS:50049105739

VL - 36

SP - 1951

EP - 1959

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 9

ER -